Idelalisib

Introduction Overview

Generic Name

idelalisib

Brand Name

Zydelig

Dosage Form

Oral tablet

Drug Class

PI3K inhibitors

Pharmacokinetics

Absorption:
Idelalisib is administered orally and is well absorbed from the gastrointestinal tract. The bioavailability allows for effective systemic exposure after oral administration. It can be taken with or without food, and food does not significantly alter the overall absorption profile, allowing flexibility in dosing. Peak plasma concentrations (Cmax) are typically achieved within 1.5 to 2.5 hours post-dose. Drug absorption is not significantly affected by gastric pH or motility, which supports its oral dosing regimen.

Distribution:
After absorption, idelalisib exhibits a moderate volume of distribution, indicating distribution into tissues beyond the vascular compartment. Plasma protein binding is high, primarily to albumin, which influences its pharmacodynamics and interaction potential. Idelalisib penetrates lymphoid tissues where target malignant B-cells reside, consistent with its efficacy in lymphoproliferative disorders. Limited central nervous system penetration has been observed, minimizing central nervous system-related effects.

Metabolism:
Idelalisib is extensively metabolized primarily by aldehyde oxidase, with minor involvement of cytochrome P450 3A enzymes, particularly CYP3A4. The predominant metabolic pathway is oxidation, forming inactive metabolites. This metabolic profile reduces the likelihood of significant CYP450-mediated drug interactions, though CYP3A4 inhibitors or inducers can affect idelalisib plasma levels and may necessitate dose adjustments. The metabolic activity underscores the need for caution when co-administered with strong CYP3A modulators.

Elimination:
The elimination half-life of idelalisib supports twice-daily dosing, typically around 8 hours. Approximately 78% of the administered dose is recovered in feces, and 15% in urine mainly as metabolites, indicating that hepatic metabolism and biliary excretion are the main routes of elimination. Renal clearance of unchanged drug is minimal. Hepatic impairment may impact metabolism and clearance, requiring careful monitoring or dose modification. Elimination kinetics ensure steady-state plasma concentrations with consistent, twice-daily oral dosing.

Dosage Forms

Available Dosage Forms:
Zydelig is available as oral tablets. The product is formulated for convenient oral administration and designed to be swallowed whole without crushing, chewing, or breaking.

Dosages for Adults and Adolescents:
The recommended adult dose for Zydelig (idelalisib) is 150 mg administered orally twice daily. This dosing continues until disease progression or unacceptable toxicity occurs. The medication is used in combination with rituximab for treating certain lymphoid malignancies, including relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL) after at least two prior systemic therapies.

Specific Patient Populations:
Use in pediatric populations under 18 years old is not approved. No specific dosage adjustments are established for elderly patients; however, monitoring for side effects is advised given the patient’s overall health. In patients with hepatic impairment, pharmacokinetics may be altered, requiring caution and potential dose modifications. Due to metabolism involving CYP3A enzymes, patients taking strong inhibitors or inducers of CYP3A may require dose adjustments or close monitoring. Pregnant women should avoid Zydelig due to potential teratogenic effects; effective contraception is warranted for both males and females during treatment and for a specified period afterward.

Tablets should be swallowed whole with or without food, and consistent dosing intervals are recommended to maintain steady-state drug levels. Management of missed doses involves taking the dose within six hours or skipping if beyond that window to avoid double dosing.

No specific tablet strengths beyond 150 mg per tablet are specified in the referenced data, indicating a single standardized tablet formulation.

Mechanism Of Action

Idelalisib selectively inhibits the delta isoform of phosphoinositide 3-kinase (PI3Kδ), an intracellular signaling enzyme predominantly expressed in leukocytes, including malignant B cells. PI3Kδ plays a critical role in the signaling pathways downstream of the B-cell receptor (BCR), which regulates cellular proliferation, survival, migration, and adhesion.

By inhibiting PI3Kδ, idelalisib disrupts the PI3K/AKT signaling cascade critical for the survival and proliferation of malignant B lymphocytes. This inhibition results in decreased production of downstream second messengers, leading to induction of apoptosis and inhibition of cell growth. Additionally, blocking PI3Kδ impairs the malignant B-cells' interaction with the microenvironment and chemokine-mediated homing to lymphoid tissues, further inhibiting disease progression.

At the cellular level, idelalisib induces apoptosis and impairs B-cell proliferation by interfering with multiple cellular survival pathways, including inhibition of AKT phosphorylation and downstream effectors. This causes a reduction in the malignant clone and interrupts the pathological lymphoproliferation seen in diseases such as chronic lymphocytic leukemia (CLL) and follicular lymphoma.

Clinically, idelalisib's targeted mechanism allows selective action on malignant B cells with a reduced impact on non-B cell lineages, offering a therapeutic advantage over traditional cytotoxic chemotherapy. This specificity underpins its use in combination with rituximab, enhancing antitumor efficacy while potentially lowering systemic toxicity.

Comparatively, other PI3K inhibitors may target different isoforms; idelalisib’s selectivity for the delta isoform aligns it specifically with hematological malignancies reliant on this pathway. Extensive clinical studies have validated this mechanism by demonstrating durable responses in relapsed and refractory lymphoid cancers with manageable safety profiles.

Pharmacological Actions

Selective inhibition of PI3K delta isoform leading to disruption of B-cell receptor signaling.
Induction of apoptosis in malignant B lymphocytes.
Inhibition of malignant B-cell proliferation and survival.
Disruption of chemokine-mediated malignant B-cell migration and adhesion.
Impairment of the tumor microenvironment supporting lymphoma growth.
Synergistic immunomodulatory effect when combined with rituximab.
Reduction in pathological lymphadenopathy and tumor burden.
Selective targeting minimizes damage to non-malignant cells compared to conventional chemotherapy.
Modulation of intracellular signaling pathways pivotal to lymphoma and chronic lymphocytic leukemia pathogenesis.
Potential immunosuppressive effects due to leukocyte PI3Kδ inhibition.

Therapeutic Or Clinical Uses

Treatment of relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab for patients unsuitable for chemotherapy.
Treatment of relapsed follicular B-cell non-Hodgkin lymphoma (FL) after at least two prior systemic therapies.
Treatment of relapsed small lymphocytic lymphoma (SLL) post two or more prior treatments.
Management of lymphoid malignancies with demonstrated efficacy in reducing tumor burden and prolonging progression-free survival.
Therapeutic option for patients with co-morbidities limiting more aggressive chemotherapeutic regimens.
Use as a targeted therapy in hematologic malignancies expressing PI3Kδ activity.
Part of combination regimens to enhance response rates in relapsed or refractory lymphomas.
Intervention aimed at disrupting malignant B-cell survival and proliferation signaling pathways.
Approved for accelerated use pending further confirmatory clinical trial data.
Alternative treatment for patients who have failed at least two prior lines of therapy.
Option to improve quality of life through oral administration with manageable adverse effect profile.
Employed in patients where immune system modulation is strategic for disease control.
Potential utility in individualized cancer therapy strategies focusing on molecular targets.

Side Or Adverse Effects

Severe diarrhea, which can be life-threatening and requires immediate medical attention.
Gastrointestinal perforation leading to serious complications.
Hepatotoxicity manifesting as elevated liver enzymes, jaundice, and liver injury.
Pulmonary toxicity including cough, wheezing, dyspnea, and interstitial lung disease.
Neutropenia and other forms of leukopenia increasing risk for infections.
Rash and severe skin reactions, including erythematous and blistering manifestations.
Fever and increased susceptibility to infections due to immunosuppression.
Nausea, vomiting, and abdominal pain as common gastrointestinal symptoms.
Fatigue and malaise associated with systemic therapy.
Easy bruising and bleeding tendencies due to hematologic toxicities.
Rare severe allergic reactions including anaphylaxis and angioedema.
Secondary malignancies with prolonged therapy, though rare.
Potential for severe mucositis and mouth sores.
Laboratory abnormalities including elevated transaminases and bilirubin.
Delayed wound healing due to immunomodulatory effects.

Precautions

Monitor liver enzymes regularly due to risk of hepatotoxicity.
Use caution in patients with pre-existing liver or lung disease.
Regular pulmonary assessments to detect early signs of lung toxicity.
Close monitoring for gastrointestinal symptoms to detect severe diarrhea or perforation.
Screen patients for history of serious skin reactions before initiating therapy.
Resume therapy cautiously in case of transient side effects; discontinue permanently if severe adverse events occur.
Avoid concurrent use with strong CYP3A inhibitors or inducers without dose adjustments.
Ensure effective contraception for both male and female patients to prevent fetal exposure.
Use in pregnancy is contraindicated due to potential fetal harm.
Advise against breastfeeding during therapy and for at least one month after the last dose.
Patients should report signs of infection promptly due to immunosuppressive action.
Periodic blood counts to monitor for neutropenia and anemia are essential.
Consider renal and hepatic function prior to initiation and during treatment.
Adjust dose or discontinue treatment in case of severe or life-threatening adverse effects.
Avoid abrupt discontinuation without physician guidance to manage toxicity.

Warnings

Risk of severe or fatal liver injury requiring close monitoring of hepatic function.
Potential for life-threatening diarrhea and colitis; prompt medical evaluation is warranted at onset of symptoms.
Risk of gastrointestinal perforations which may be fatal if untreated.
Severe respiratory adverse reactions including pneumonitis and interstitial lung disease.
Patients may develop serious infections due to immunosuppression (neutropenia).
Serious skin reactions including Stevens-Johnson syndrome or toxic epidermal necrolysis can occur.
Idelalisib can cause fetal harm; pregnancy must be avoided during treatment.
Risk of severe hypersensitivity reactions necessitating immediate discontinuation.
Delays in cancer treatment or discontinuation may be necessary if severe adverse effects occur.
Avoid use in pediatric patients due to lack of established safety and efficacy.
Concomitant administration with strong CYP3A inhibitors or inducers may alter drug levels leading to toxicity or reduced efficacy.
Risk of venous thromboembolism reported; monitor patients closely.
Potential for secondary immune complications due to delta isoform inhibition.
Patients should be educated about early reporting of symptoms suggestive of serious adverse effects.
Use only under strict medical supervision with appropriate laboratory and clinical monitoring.

Contraindication

Known allergy or hypersensitivity to idelalisib or any component of the formulation.
Pregnancy due to teratogenic risk and potential fetal harm.
Breastfeeding while on therapy and for at least one month after discontinuation.
Severe hepatic impairment without possibility for close monitoring and dose adjustment.
History of serious or severe skin reactions to idelalisib or similar compounds.
Patients with unresolved severe infections before initiation of treatment.
Concurrent use with drugs contraindicated due to interaction potential without careful management.
Pediatric patients under the age of 18 years due to lack of safety data.
Patients with active severe gastrointestinal conditions that pose high risk during therapy.
Uncontrolled pulmonary disease that may elevate risk for severe respiratory toxicity.
Known severe neutropenia or immunocompromised states without reversal prior to therapy.
Patients unable to adhere to strict monitoring and follow-up regimens.
Concomitant use of drugs leading to increased bleeding risk without possibility for management.
Patients with perforation of the intestines contraindicated to continue therapy.
Use is contraindicated in patients who have experienced serious adverse reactions during previous idelalisib treatment.

Drug Interactions

Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin) may increase idelalisib plasma levels, raising risk of toxicity.
Strong CYP3A inducers (e.g., rifampin, carbamazepine) can reduce idelalisib efficacy by decreasing plasma concentration.
Concomitant use with rituximab enhances therapeutic efficacy but requires monitoring for additive toxicities.
Co-administration with other immunosuppressants increases risk of infections.
Potential interactions with anticoagulants and antiplatelet agents may increase bleeding risk.
Drugs affecting hepatic enzymes may alter metabolism and clearance of idelalisib.
Interactions with acid-reducing agents are not significant but monitoring is advised.
Herbal supplements such as St. John's Wort may induce CYP3A and decrease idelalisib plasma levels.
Avoid concurrent use with other drugs known to cause hepatotoxicity to prevent additive liver injury.
Interactions with strong inhibitors of aldehyde oxidase, although less common, may impact metabolism.
Concomitant use of nephrotoxic agents should be carefully evaluated to avoid renal complications.
Co-administration with CYP3A substrates may require dosage adjustments of the substrate drug due to altered enzyme availability.
Monitoring is advised when combining with drugs that can prolong QT interval though idelalisib’s direct effect is minimal.
Caution when using with vaccines or immunotherapies due to altered immune responses.
Potential for additive pulmonary toxicity if combined with other agents affecting lung function.

Preparations Of The Drug

Zydelig is supplied as oral tablets intended for twice-daily administration.
Each tablet contains 150 mg of idelalisib active ingredient.
Tablets are formulated to be swallowed whole without crushing, chewing, or splitting.
Packaged in moisture-resistant containers to maintain stability.
Supplied with detailed prescribing information and patient medication guides.
Stored at controlled room temperature away from moisture and heat.
Contains inactive ingredients that support tablet integrity and bioavailability.
Each bottle contains a set number of tablets to cover treatment cycles as prescribed.
Labeling includes clear dosage instructions and warnings.
Available through prescription only with restricted distribution in some regions.
Manufactured according to Good Manufacturing Practice (GMP) standards to ensure quality and consistency.
Packaging designed to minimize contamination and ensure patient safety.
Includes tamper-evident features to maintain drug integrity.
Patient support programs offered for information and assistance with therapy adherence.
Compatible with standard oral administration practices for oncology medications.